Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...
On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a favorable opinion analyzing a pharmaceutical manufacturer’s ...
On June 17, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted a favorable Advisory Opinion 24-03 (“AO 24-03”) involving a pharmaceutical manufacturer’s ...
Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine Oral anticancer medications (OAMs) are high priced with a ...
Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting ...
When Gury Doshi, MD, learned that a patient’s insurance didn’t cover her breast cancer medication, Doshi had a potential workaround. The patient could try to bypass the insurer and access the drug at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback